Viatris (VTRS) revenue breakdown
By segment, Developed Markets is the largest at 60% of fiscal 2025 revenue; Greater China grew fastest, 46% a year over 7 years.
By product, Brands is the largest at 64% of fiscal 2025 revenue, growing 8% a year over 7 years.
Revenue by segment
Fiscal years, as Viatris reports them in its 10-K filings; fiscal 2025 total $14.3B.
| Segments | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Developed Markets | $8.3B | $8.2B | $8.5B | $10.4B | $9.8B | $9.3B | $8.9B | $8.5B | 60% |
| Greater China | $168M | $215M | $260M | $2.2B | $2.2B | $2.2B | $2.2B | $2.3B | 16% |
| Emerging Markets | $1.7B | $1.7B | $1.9B | $3.1B | $2.6B | $2.6B | $2.3B | $2.2B | 16% |
| JANZ | $1.1B | $1.2B | $1.2B | $2.0B | $1.6B | $1.4B | $1.3B | $1.2B | 8% |
Revenue by product
Fiscal years, as Viatris reports them in its 10-K filings; fiscal 2025 total $14.3B.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Brands | $5.5B | $5.4B | $5.2B | $10.8B | $9.9B | $9.8B | $9.2B | $9.2B | 64% |
| Generics | $5.2B | $4.8B | $5.3B | $7.0B | $6.3B | $5.6B | $5.5B | $5.1B | 36% |
| Complex Gx and Biosimilars | $523M | $1.2B | $1.3B | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VTRS.
Open VTRS in InvestinglyQuestions
Where does Viatris make its money?
In fiscal 2025, by segment: Developed Markets $8.5B, Greater China $2.3B, Emerging Markets $2.2B, JANZ $1.2B.
From Viatris's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.